文献速递认知障碍与痴呆

阿尔茨海默病阶段与APOE ε4基因型影响脑脊液生物标志物的性别差异

Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype.
PubMed 文献 · Neurology · 2020-08-11

研究纳入1801名受试者(AD痴呆937例、MCI 437例、SCD 427例),分析脑脊液Aβ42、t-Tau和p-Tau的性别差异,并考虑疾病阶段和APOE ε4基因型的修饰作用。结果显示,APOE ε4携带者中女性在SCD和MCI阶段p-Tau较高,而非携带者中女性在MCI和AD痴呆阶段p-Tau较高。

要点

  • APOE ε4携带者中,女性在SCD和MCI阶段脑脊液p-Tau显著高于男性。
  • APOE ε4非携带者中,女性在MCI和AD痴呆阶段脑脊液p-Tau显著高于男性。
  • 脑脊液Aβ42未见显著性别差异。

核心结论

  • 在APOE ε4携带者中,脑脊液p-Tau的性别差异在疾病早期阶段更明显。
  • 在APOE ε4非携带者中,性别差异在疾病晚期阶段更明显。
  • APOE ε4对脑脊液生物标志物性别差异的影响取决于AD疾病阶段。

研究设计与样本

  • 纳入1801名参与者,包括AD痴呆937例、MCI 437例和SCD 427例。
  • 采用线性回归分析检验性别、疾病阶段和APOE ε4的三阶交互作用,并对年龄进行校正。
  • 主要结局为脑脊液Aβ42、t-Tau和p-Tau水平。

主要发现

  • 三阶交互作用对t-Tau(p < 0.001)和p-Tau(p < 0.01)显著,对Aβ42不显著。
  • APOE ε4携带者中,女性在SCD阶段t-Tau的Cohen d为0.52(95%CI 0.19-0.84,p < 0.001),p-Tau为0.44(95%CI 0.11-0.77,p = 0.004);在MCI阶段t-Tau为0.54(95%CI 0.28-0.80,p < 0.001),p-Tau为0.52(95%CI 0.26-0.77,p < 0.001);在AD痴呆阶段无显著差异。
  • APOE ε4非携带者中,女性在MCI阶段t-Tau的Cohen d为0.49(95%CI 0.17-0.80,p = 0.002),p-Tau为0.47(95%CI 0.16-0.78,p = 0.003);在AD痴呆阶段t-Tau为0.42(95%CI 0.19-0.65,p < 0.001),p-Tau为0.38(95%CI 0.15-0.61,p = 0.002);在SCD阶段无显著差异。

临床怎么用

  • 解读脑脊液p-Tau和t-Tau的性别差异时,应结合APOE ε4基因型和疾病阶段。
  • 对APOE ε4携带的早期阶段女性患者,需关注更高的p-Tau水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate sex differences in CSF biomarkers, taking the potential modifying role of clinical disease stage and APOE ε4 genotype into account. METHOD: We included participants (n = 1,801) with probable Alzheimer disease (AD) dementia (n = 937), mild cognitive impairment (MCI; n = 437), and subjective cognitive decline (SCD; n = 427). Main outcomes were CSF β-amyloid1-42 (Aβ42), total tau (t-Tau), and tau phosphorylated at threonine 181 (p-Tau) levels. Age-corrected 3-way interactions between sex, disease stage (i.e., syndrome diagnosis at baseline), and APOE ε4 were tested with linear regression analyses for each outcome measure. In case of significant interactions (p < 0.05), sex differences were further evaluated by stratifying analyses for clinical disease stage and APOE ε4 genotype, including age as a covariate. RESULTS: Three-way interactions were significant for t-Tau (p < 0.001) and p-Tau (p < 0.01) but not Aβ42. In APOE ε4 carriers, women showed higher p-Tau concentrations than men in SCD (Cohen d [95% confidence interval]: t-Tau = 0.52 [0.19-0.84], p < 0.001; p-Tau = 0.44 [0.11-0.77] p = 0.004) and MCI (Cohen d [95% CI]: t-Tau = 0.54 [0.28-0.80], p < 0.001; p-Tau = 0.52 [0.26-0.77], p < 0.001) but not in AD dementia. In APOE ε4 noncarriers, women showed higher p-Tau concentrations in MCI (Cohen d [95% CI]: t-Tau = 0.49 [0.17-0.80], p = 0.002; p-Tau = 0.47 [0.16-0.78], p = 0.003) and AD dementia (Cohen d [95% CI]: t-Tau = 0.42 [0.19-0.65], p < 0.001; p-Tau = 0.38 [0.15-0.61] p = 0.002) but not in SCD. CONCLUSIONS: Within APOE ε4 carriers, sex differences in CSF p-Tau are more evident in early disease stages, whereas for APOE ε4 noncarriers, sex differences are more evident in advanced disease stages. These findings suggest that the effect of APOE ε4 on sex differences in CSF biomarkers depends on disease stage in AD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Babapour Mofrad R, Tijms BM, Scheltens P, et al. Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype. Neurology. 2020. PMID: 32788242. doi:10.1212/WNL.0000000000010629

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。